Vascular Solutions LLC
VASC
NASDAQ56.00
USD
- -
- -
Vascular Solutions LLC
VASC
(NASDAQ)
Recent
price
56.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Vascular Solutions, Inc. (VASC) develops and markets medical devices for minimally invasive coronary and peripheral vascular procedures; its core products include GuideLiner guide extension catheters, Pronto extraction catheters, vein catheter reprocessing services, micro-introducer kits, hemostatic patches such as D-Stat Flowable hemostat, radial access products, Langston catheters, Trapliner catheters, guidewires, snare and retrieval devices, and laser procedure kits for varicose vein treatment, encompassing over 90 products and approximately 900 stock keeping units sold to interventional cardiologists, radiologists, electrophysiologists, and vein specialists. The company operates globally through direct sales in the United States and distributors internationally, targeting healthcare providers in the vascular intervention sector. Founded in 1996 and headquartered in Minneapolis, Minnesota, Vascular Solutions was acquired by Teleflex Incorporated in February 2017 for $56 per share in a transaction valued at approximately $1 billion, integrating its technologies into Teleflex's vascular access and interventional portfolio to accelerate growth in coronary and peripheral markets. Post-acquisition, Vascular Solutions' products contribute to Teleflex's expanded offerings exceeding 150 cardiac, vascular, and interventional access items, with its pipeline supporting complex interventions, radial access, and embolization procedures. As of 2025, these legacy assets remain part of Teleflex's operations amid ongoing integration efforts, including a restructuring plan approved in late 2025 for sales force realignment and manufacturing relocations related to broader vascular intervention expansions.